Status: Recruiting
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
This study is an open-label, exploratory, prospective clinical trial with dose escalation(according to "3+3" design), to evaluate the safety and tolerability of QH103(Universal CD19 CAR-γδT Cell Injection)in the treatment of recurrent/refractory antibody-mediated neurological autoimmune diseases.
Participants needed: 6
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Tongji HospitalUpdated: May 12, 2026Locations: 1
Eligibility criteria
Aged 18-75 years (inclusive), any gender. [+21]
History of severe drug allergy or allergic diathesis. [+20]